ArticleAmerican journal of translational research2021
Immunomodulatory function of the active ingredients in traditional Chinese prescriptions on early stage esophageal cancer with dysplasia.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effects of the ingredients in a traditional Chinese prescription on the immune regulation of esophageal cancer in patients with early atypical hyperplasia.
methodsA total of 60 C57BL mice were randomly selected as the positive control group; another 240 C57BL mice were randomly divided into a blank control group (n=30), a 4NQO group (n=60) and an experimental group (n=120). The experimental group was divided into the prevention group which received carcinogens and the prescription composition simultaneously, and the treatment group which received carcinogens first and the prescription composition second. The lymphocyte proliferation responses in peripheral blood and spleen cells were determined, and the changes of CD4
resultsThe CD4
conclusionThe composition of traditional Chinese prescriptions can improve antitumor immunity and slow down the development of esophageal precancerous lesions by inhibiting the expression of T cells on lymphocytes and the positive expression of B7H4 and CD4
Indexed as
Identifiers
33841688PMC8014365W3154677348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.